dasatinib and ponatinib

dasatinib has been researched along with ponatinib* in 1 studies

Other Studies

1 other study(ies) available for dasatinib and ponatinib

Article	Year
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects. Journal of medicinal chemistry, 2020, 08-13, Volume: 63, Issue:15 The BCR-ABL fusion oncoprotein causes chronic myeloid leukemia or acute lymphoblastic leukemia in Ph Topics: Antineoplastic Agents; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imidazoles; Models, Molecular; Niacinamide; Proteolysis; Pyrazoles; Pyridazines	2020

Article

Year

Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.

Journal of medicinal chemistry, 2020, 08-13, Volume: 63, Issue:15

The BCR-ABL fusion oncoprotein causes chronic myeloid leukemia or acute lymphoblastic leukemia in Ph

Topics: Antineoplastic Agents; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imidazoles; Models, Molecular; Niacinamide; Proteolysis; Pyrazoles; Pyridazines

2020